KURA News and Press, Kura Oncology Inc. From 08/15/19

The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...

SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kathleen Ford as Chief Operating Officer, effective i...

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Off...

Kura Oncology, Inc. (KURA) Q2 2019 Earnings Conference Call August 01, 2019 4:30 PM ET Company Participants Pete De Spain - Vice President of Investor Relations Troy Wilson - President & Chief Executive Officer Marc Grasso - Chief Financial Officer & Chief Business Office...

The following slide deck was published by Kura Oncology, Inc. in conjunction with their 2019 Q2 earnings Read more ...

Kura Oncology (NASDAQ: KURA ): Q2 GAAP EPS of -$0.38 beats by $0.03 . More news on: Kura Oncology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – – Additional Phase 2 data in HRAS mutant HNSCC, other SCCs and AITL ant...

Kura Sushi USA (NASDAQ: KURA ) has priced its initial public offering of 2.9M Class A common stock at $14.00 per share. More news on: Kura Oncology, Inc., Read more ...

SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2019 financial results after the clos...

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...